Cystic fibrosis. Mucoviscidosis
Conditions
Interventions
Tablet sildenafil
first: 1mg/kg/day in 3 times for 1 week and then 1mg/kg/dose 3 times in day for 3 months..
Treatment - Drugs
first: 1mg/kg/day in 3 times for 1 week and then 1mg/kg/dose 3 times in day for 3 months.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
8 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Confirmed CF with respiratory; gastrointestinal or urogenital symptom with positive test for CF in two times; (CL>60) male and female more than 8 years with potency of doing spirometry; stable vital sign without upper or lower respiratory tract infection; FEV1>50%. Exclusion criteria: History of sensitivity to sildenafil or daily usage of systemic corticostroid or ibuprofen; LFT>3*normal; biliary cirhosis; portal hypertention; heart diseases such as aortic stenosis, arrhythmia, coronary artery disaeaes; neurological or hematologic or renal disaeas; takingof alfa blocker or nitrate or calcium blocker or CYP3A4 inhibitor such as ketoconazole or erythromycin; history of migraine; druge sensitivity or side effect or no patient inclination to continuation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FEV1/FVC. Timepoint: Before the study and 3months after the start. Method of measurement: Spirometry.;FEV1. Timepoint: Befor the study and 3 months after the stsrt. Method of measurement: Spirometry.;FEF25-75. Timepoint: Before the study and 3months after the start. Method of measurement: Spirometry.;Walking tolerance. Timepoint: Before the study and 3montha after the start. Method of measurement: Minute, ET test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug sensitivity. Timepoint: Weekly. Method of measurement: History. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohsen reisi
Esfahan University of Medical Sciences
Outcome results
None listed